GRPR and cancer: Yet, the molecular mechanism for the increased uptake and radiosensitizing effects of mTORC1 inhibitor rapamycin to [177Lu]Lu-RM2 in GRPR-positive cancers has not been elucidated and this point warrants further investigation.